Cingulate Inc

CING · NASDAQ · Healthcare / Biotechnology

4.30USD-0.19 (-4.23%)

Price History

Full chart

Market Stats

Previous Close4.49

Open4.44

Day Range4.18 – 4.60

52-Week Range3.16 – 11.89

Volume177.47K

Market Cap73.58M

P/E (TTM)0.00

Forward P/E0.00

EPS-3.64

Dividend Yield0.00%

Beta-0.89

50-Day Avg5.07

200-Day Avg5.38

About

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Shane J. Schaffer Pharm.D.
Employees14
Headquarters1901 West 47th Place, Kansas City, KS, United States, 66205, USA
Websitehttps://www.cingulate.com

Leadership

Dr. Shane J. Schaffer Pharm.D.Co-Founder, CEO & Chairman of the Board · b. 1975
Dr. Matthew N. Brams M.D.Co-Founder, Executive VP & Chief Medical Officer · b. 1964
Ms. Jennifer L. Callahan CPAExecutive VP, CFO & Secretary · b. 1971
Dr. Raul R. Silva M.D.Co-Founder, Executive VP & Chief Science Officer · b. 1958
Mr. Thomas DaltonVice President of Investor & Public Relations
Mr. Downey Bryan WadeExecutive VP & Chief Commercial Officer · b. 1972

Financials

Income Statement

Currency: USD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	0	0	0	0	0	0
Cost of Revenue	178.91K	842.35K	808.44K	621.99K	582.92K	653.09K	540.89K
Gross Profit	-178.91K	-842.35K	-808.44K	-621.99K	-582.92K	-653.09K	-540.89K
Operating Expense	11.47M	6.24M	19.87M	16.88M	22.18M	14.99M	19.40M
Operating Income	-11.65M	-7.08M	-20.68M	-17.50M	-22.76M	-15.64M	-19.94M
EBITDA	-11.47M	-6.24M	-19.97M	-17.11M	-22.18M	-14.99M	-19.40M
Net Income	-11.55M	-7.18M	-20.71M	-17.85M	-23.53M	-16.56M	-22.45M
R&D	9.09M	5.09M	8.41M	9.00M	15.49M	9.45M	9.77M
Interest Expense	0	54.60K	33.41K	174.00K	776.00K	99.00K	924.45K

Balance Sheet

Currency: USD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	5.28M	5.79M	22.89M	11.41M	3.49M	14.86M	15.07M
Total Liabilities	4.66M	4.50M	2.04M	7.52M	10.36M	7.41M	12.56M
Total Equity	615.88K	1.29M	20.84M	3.88M	-6.87M	7.46M	2.51M
Cash	418.47K	1.20M	16.49M	5.36M	52.42K	12.21M	10.95M
Total Debt	2.09M	2.05M	1.18M	5.87M	3.51M	5.10M	8.79M
Net Debt	1.67M	848.99K	-15.32M	509.77K	3.46M	-7.11M	-2.17M

Cash Flow

Currency: USD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-9.53M	-6.81M	-10.43M	-15.88M	-15.03M	-18.45M	-17.25M
Investing Cash Flow	2.74M	-384.17K	-814.74K	-152.65K	-224.10K	-211.80K	-162.00K
Financing Cash Flow	6.14M	7.97M	26.54M	4.90M	9.95M	30.82M	16.15M
Capital Expenditure	1.02M	402.10K	814.74K	153.42K	224.10K	211.80K	162.14K
Free Cash Flow	-10.55M	-7.21M	-11.25M	-16.04M	-15.26M	-18.66M	-17.41M
FCF to OCF	110.66%	105.90%	107.81%	100.97%	101.49%	101.15%	100.94%

Earnings

Report Date	Sep 27, 2021	Dec 9, 2021	Mar 10, 2022	May 12, 2022	Aug 11, 2022	Nov 14, 2022	Mar 10, 2023	May 10, 2023	Aug 14, 2023	Nov 13, 2023	Mar 31, 2024	Apr 1, 2024	Aug 13, 2024	Nov 7, 2024	Mar 27, 2025	May 8, 2025	Aug 19, 2025	Nov 13, 2025	Mar 18, 2026	May 14, 2026	Aug 13, 2026	Nov 12, 2026
EPS Estimate	0.00	0.00	-0.39	-56.40	-139.20	-88.80	-0.37	-77.60	-81.60	-90.40	-4.86	-52.72	-4.92	-2.22	-2.93	-0.98	-0.82	-0.75	-1.55	-0.53	-0.63	-0.48
EPS Actual	-0.35	-1.38	-0.32	-105.60	-86.40	-86.40	-0.41	-84.00	-136.80	-72.00	-7.66	-19.20	-5.47	-1.83	-3.68	-1.04	-1.09	-1.35	-0.84	-0.95	-0.45	-
Surprise	-	-	17.95%	-87.23%	37.93%	2.70%	-10.81%	-8.25%	-67.65%	20.35%	-57.61%	63.58%	-11.18%	17.57%	-25.60%	-6.12%	-32.93%	-80.00%	45.81%	-79.25%	28.57%	-
Timing	-	After-hours	Pre-market	After-hours	Pre-market	Pre-market	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	Pre-market	Pre-market	-	After-hours	Pre-market	After-hours	-	Pre-market	Pre-market	-

Key Statistics & Ratios

Market Cap73.58M

Enterprise Value50.02M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book3.20

EPS-3.64

Book Value1.69

Revenue (TTM)0

Gross Profit (TTM)-8.52M

EBITDA-24.47M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-198.74%

Return on Assets-66.94%

Shares Outstanding14.54M

Shares Float14.21M

Beta-0.89

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Buy

Based on 4 analystsTarget 21.20

Strong Buy
1
Buy
3

Ownership Breakdown

Institutions: 12.62%
Insiders: 28.29%
Retail / Other: 59.09%

Top Institutional Holders

Vanguard Capital Management, LLC
308.97K2.12%
Chicago Partners Investment Group LLC
188.43K1.30%
Kestra Advisory Services, LLC
151.50K1.04%
Geode Capital Management, LLC
101.37K0.70%
Marshall Wace Asset Management Ltd
92.93K0.64%
Jane Street Group LLC
90.87K0.62%
XTX Topco Ltd
53.50K0.37%
BCV Asset Management Inc.
51.20K0.35%
Vanguard Fiduciary Trust Co
50.07K0.34%
HRT FINANCIAL LLC
33.14K0.23%
Renaissance Technologies Corp
31.89K0.22%
Quantum Private Wealth, LLC
30.00K0.21%
Prospera Financial Services Inc
29.90K0.21%
State Street Corp
27.59K0.19%
Virtu Financial LLC
27.53K0.19%
BlackRock Inc
23.27K0.16%

Top Fund Holders

Vanguard MStar Total Stk Mkt Idx Invest
394.56K2.71%
Fidelity Extended Market Index
68.67K0.47%
iShares Micro-Cap ETF
27.81K0.19%
Fidelity Total Market Index
22.53K0.15%

Stock Splits

Aug 9, 20241:12
Nov 30, 20231:20